NASDAQ:CYTK - Cytokinetics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.78 -0.57 (-6.83 %)
(As of 10/19/2018 06:11 AM ET)
Previous Close$8.35
Today's Range$7.74 - $8.43
52-Week Range$6.20 - $15.43
Volume1.05 million shs
Average Volume325,808 shs
Market Capitalization$456.14 million
P/E Ratio-3.00
Dividend YieldN/A
Beta1.42
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000

Debt

Debt-to-Equity Ratio0.41
Current Ratio8.95
Quick Ratio8.95

Price-To-Earnings

Trailing P/E Ratio-3.00
Forward P/E Ratio-3.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.37 million
Price / Sales31.79
Cash FlowN/A
Price / CashN/A
Book Value$2.04 per share
Price / Book3.81

Profitability

EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net MarginsN/A
Return on Equity-121.07%
Return on Assets-45.51%

Miscellaneous

Employees137
Outstanding Shares54,630,000
Market Cap$456.14 million

Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How were Cytokinetics' earnings last quarter?

Cytokinetics, Inc. (NASDAQ:CYTK) issued its quarterly earnings data on Thursday, July, 26th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.51). The biopharmaceutical company earned $6.22 million during the quarter, compared to analyst estimates of $5.54 million. View Cytokinetics' Earnings History.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, October 25th 2018. View Earnings Estimates for Cytokinetics.

What price target have analysts set for CYTK?

7 equities research analysts have issued 1 year price objectives for Cytokinetics' shares. Their predictions range from $10.00 to $21.00. On average, they anticipate Cytokinetics' share price to reach $13.4286 in the next year. This suggests a possible upside of 72.6% from the stock's current price. View Analyst Price Targets for Cytokinetics.

What is the consensus analysts' recommendation for Cytokinetics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

What are Wall Street analysts saying about Cytokinetics stock?

Here are some recent quotes from research analysts about Cytokinetics stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month price target of $14. CYTK hosted a R&D Day during which it provided incremental updates on its programs and broadening pipeline. Takeaways include design of the second P3 study of ome’ called METEORIC-HF, which we are enthusiastic to see as it will evaluate exercise tolerance in patients with HF. METEROIC data are expected in 2021, and we believe a positive outcome would brightline the differentiated clinical profile vs. current SOC. Additionally, data from the primary study for regulatory purposes, GALACTIC-HF, are expected in 2021, with interim reads in 2019 (futility) and 2020 (efficacy) that may yield milestone payments to the company." (10/17/2018)
  • 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (10/3/2018)

Who are some of Cytokinetics' key competitors?

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the folowing people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
  • Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
  • Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $7.78.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $456.14 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is http://www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]


MarketBeat Community Rating for Cytokinetics (NASDAQ CYTK)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  500 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  674
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2018 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel